Conexeu Sciences (CNXU) and a Third Option in Breast Reconstruction

Opening Summary

For more than half a century, rebuilding a breast after cancer has meant one of two things: put a device in, or move tissue over from somewhere else.²⁵ Implants come with an FDA warning that they are not lifetime devices.¹ Tissue-moving surgeries leave a second wound. And across a large national study, roughly two out of three mastectomy patients did not get immediate reconstruction at all.²

That’s not a small niche. The American Cancer Society expects about 321,910 new invasive breast cancer cases in U.S. women in 2026³, and U.S. surgeons performed 162,579 breast reconstructions in 2024.⁴ Since 1998, federal law has required most group health plans that cover mastectomy to also cover reconstruction.⁵ It’s a large, recurring, insured market that has run on the same two ideas for decades.

Conexeu Sciences (NASDAQ: CNXU) wants to add a third. Its B.R.E.A.S.T.™ device candidate is a 3D-bioprinted, resorbable breast matrix designed to give the body a temporary framework to grow its own tissue back, then disappear.⁶ B.R.E.A.S.T.™ is investigational and in preclinical development, according to Conexeu’s May 19, 2026 release, and has not been submitted to, cleared or approved by the FDA.⁶ Conexeu has launched a preclinical program at the Wake Forest Institute for Regenerative Medicine⁷, and the same underlying material is headed for its first FDA submission, in wound care, in early 2027.⁸ The company’s statement is forward-looking. Its actual results may differ; see the cautionary language in its Form 10-Q for the quarter ended July 31, 2026 and its press release dated October 6, 2026.

Here’s the investment case, why the last five months matter, and what’s still unproven.

Key Figures

Full source citations are numbered inline and listed in the Sources section below.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →

Two Options, Fifty Years

Look closely at breast reconstruction today and the established choices fall into two buckets, split by how they work rather than by brand name.

Device-based: implants. Implants dominate. In 2022, about 118,000 of roughly 151,600 U.S. breast reconstructions were implant-based, nearly 4 out of 5.⁹ Since 2021, every breast implant in the U.S. has carried an FDA boxed warning. The labeling tells patients implants are not lifetime devices, that reoperation and removal are among the most common complications, and that implants carry a risk of a lymphoma called BIA-ALCL.¹ The FDA puts the lifetime risk of BIA-ALCL with textured implants at between 1 in 3,817 and 1 in 30,000.¹¹ In 2024, U.S. surgeons removed implants in 26,600 reconstruction patients⁴ and 41,271 cosmetic augmentation patients.¹²

An implant is a bit like a roof with a warranty. It works, but everyone knows a replacement is coming.¹

Relocation-based: moving the patient’s own tissue. Flap surgeries move skin, fat and sometimes muscle, often from the abdomen, to rebuild the breast. Results can be natural and lasting, but it’s a long operation that creates a second wound. Fat grafting is less invasive, but published estimates put the share of grafted fat that survives anywhere from 30% to 70%, which makes results hard to predict.¹³

The empty middle. The industry has tried an injectable. Galderma’s Q-Med marketed Macrolane®, a hyaluronic acid gel, for breast enhancement, then discontinued that use in 2012 because the product could interfere with reading mammograms.¹⁴ That leaves a gap between a foreign body and a major tissue-moving surgery, and few established options filling it, though several companies are now developing resorbable implants.

On implant-based reconstruction: “…replacing what was lost with a foreign body.”

Miles D. Harrison, President and CEO, Conexeu Sciences⁶

What Just Happened, and Why It Matters

Over the past five months, Conexeu has put four building blocks in place. Each one maps to a specific piece of the investment case.

May 19, 2026: B.R.E.A.S.T.™ unveiled. Conexeu introduced a 3D-bioprinted breast matrix built on its CXU™ platform and designed to move reconstruction from replacement toward regeneration.⁶

Why it matters: This points a platform the company already owns at one of the most valuable, insured procedures in plastic surgery. As co-founder Dr. Claudia Chavez-Munoz put it: “We did not set out to design a better implant. We set out to eliminate the need for one.”⁶ If that works, it isn’t a better product in an old category. It’s a new category.

May 27: a preclinical program at Wake Forest. Conexeu launched a preclinical program for B.R.E.A.S.T.™ at the Wake Forest Institute for Regenerative Medicine, using WFIRM’s bioprinting infrastructure through the nonprofit RegenMed Development Organization (ReMDO). The study will evaluate the matrix’s durability, how well it integrates with host tissue, and how it resorbs.⁷

Why it matters: Durability, integration and resorption are the three questions that decide whether a regenerative breast matrix can work at all. Access to WFIRM’s facilities gives the program a named, checkable milestone.

July 7 and 14: the large-volume arm. Conexeu’s 12-month P.R.O.O.F. preclinical study reported meeting its objectives in a large-volume, 200cc-equivalent model.¹⁵[*12]

Why it matters: P.R.O.O.F. tested the injectable form, not the printed B.R.E.A.S.T.™ matrix. But the question every investor should ask about a resorbable breast scaffold is whether the underlying material can support volume restoration at anything like breast scale. P.R.O.O.F. is the company’s first large-volume test of that question, in animals, and the company reports its objectives were met.

October 6: the same material moves toward its first FDA filing. Conexeu said multiple scaled-up batches of CXU™ material met specification and that its wound-care 510(k) submission remains on track for the first quarter of 2027.⁸

Why it matters: Conexeu builds everything on one platform.⁸ A wound-care clearance would give the company its first commercial product, real manufacturing experience and a stronger hand in raising the money the longer breast program will need. On our reading of the October 6 release, and assuming the 510(k) is cleared and sales follow, the wound program could help fund the breast program. This is our view, not a forecast by the company.

How It’s Supposed to Work

Here’s an analogy. Building a house means putting up a frame first, then walls. Implants fill the space with a finished device. B.R.E.A.S.T.™ aims to put up the frame, let the body do the construction, and take the scaffolding down when it’s done.

B.R.E.A.S.T.™ is made from CXU™, a multi-component collagen-based ECM scaffold, modeled on the natural mesh that holds tissue together.⁷[*1] Because it’s 3D-printed, each matrix could in principle be shaped from a patient’s own scan.⁶ It’s designed to be temporary: the patient’s cells are meant to move in and populate the scaffold while the matrix gradually resorbs, rather than leaving a foreign object behind.⁷[*9][*10]

CXU™ itself has more than a decade of university research behind it. In peer-reviewed preclinical studies dating back to 2011,[*1] it has been characterized for host-cell infiltration[*9][*10], blood-vessel ingrowth[*3][*6], integration[*10] and inflammatory profile.[*10] Conexeu owns its platform patents outright, with patents issued in the U.S., EU, Japan and Australia and pending in Canada, with no royalty or licensing obligations.⁸

The company is clear about the limit: none of its cited studies evaluated CXU™ in breast tissue. Breast-specific evidence is being developed now.⁶

Why Reconstruction First

Conexeu could have aimed B.R.E.A.S.T.™ at cosmetic augmentation. B.R.E.A.S.T.™ is being developed for reconstruction; no cosmetic indication is planned or claimed. In our opinion, starting with reconstruction is the smarter commercial move, for three reasons.

1. A reimbursement floor. Federal law requires most group health plans that cover mastectomy to also cover reconstruction.⁵ Demand here isn’t driven by discretionary spending the way cosmetic procedures are. Coverage for any future Conexeu product has not been determined.
2. Every defect is unique. In our view, reconstruction is where a printed, patient-specific structure could differ most from one-size-fits-many implants.
3. The current options carry trade-offs. Implant removals and reoperations are routine⁴, and many patients skip immediate reconstruction altogether.² In our view, a credible third option would find interest.

The Market: What Buyers Have Already Paid

The best evidence that breast reconstruction is a real business comes from what large companies have paid just for the supporting materials.

In most implant reconstructions, surgeons use a sheet of processed tissue called an acellular dermal matrix to help hold the implant in place. It was used in about 76,000 U.S. reconstructions in 2022.⁹ And as of Integra’s late-2022 deal announcement, no surgical matrix was FDA-approved specifically for implant-based breast reconstruction.¹⁶

Notice two things. First, the same matrix business changed hands twice. Second, Integra agreed to pay $50 million upfront and up to $90 million more in contingent payments for a business with about $5 million in 2022 sales; in its December 1, 2022 release, Integra called the global breast reconstruction market an attractive growth opportunity for its surgical reconstruction business.¹⁹ Integra put the global market for these matrices at $600 million.²⁰ Conexeu has not announced any acquisition discussions; these deals are market context, not a prediction.

The broader markets are growing too. Third-party research cited by Conexeu puts breast reconstruction at about $2.16 billion in 2024, rising to $3.15 billion by 2030, and breast implants at about $2.21 billion in 2025, rising to $3.21 billion by 2030.²¹ Global Market Insights sizes 3D bioprinting at $1.6 billion in 2023, heading to $6.5 billion by 2032.²²

Conexeu Sciences (Nasdaq: CNXU): 10 Points to Weigh

1. The Need Is Large and Recurring

The American Cancer Society expects about 321,910 new invasive breast cancer cases in U.S. women in 2026,³ and U.S. surgeons performed 162,579 breast reconstructions in 2024.⁴ In a large national study, about two in three mastectomy patients did not get immediate reconstruction.² The need comes back every year.

2. Reconstruction Is Covered by Law

Since 1998, federal law has required most group health plans that cover mastectomy to also cover reconstruction.⁵ That covers reconstruction, not any particular product; coverage for any future Conexeu product has not been determined.

3. Implants Carry a Boxed Warning

Since 2021, every breast implant in the U.S. has carried an FDA boxed warning: implants are not lifetime devices, and reoperation and removal are among the most common complications.¹ In 2024, U.S. surgeons removed implants in 26,600 reconstruction patients.⁴

4. The Middle Ground Has Few Established Options

Flap surgery leaves a second wound, and published estimates put fat-graft survival anywhere from 30% to 70%.¹³ The one injectable tried for the breast, Macrolane®, lost that use in 2012 over mammography concerns.¹⁴ In our view, few established products sit between a foreign body and a major tissue-moving surgery.

5. The Goal Is a Scaffold the Body Populates

B.R.E.A.S.T.™ is a 3D-bioprinted, resorbable matrix designed to give the body a temporary framework: the patient’s cells are meant to populate it while it gradually resorbs.^6,7[*9][*10] It is investigational and has not been tested in breast tissue or in people.

6. Each Matrix Could Be Shaped From a Scan

Conexeu says CT scans could be used to create structures tailored to each patient’s anatomy.⁶ In our view, reconstruction, where every defect is different, is where that design choice would matter most.

7. Buyers Have Paid for Reconstruction Materials

Allergan paid $2.9 billion in cash for LifeCell, maker of tissue matrices widely used in breast reconstruction,¹⁰ and Integra agreed to pay $50 million upfront and up to $90 million more in contingent payments for Surgical Innovation Associates.¹⁹ Both bought businesses with products already in use; Conexeu has neither revenue nor breast data yet.

8. A Named Lab Is Running the First Tests

Conexeu launched a preclinical program for B.R.E.A.S.T.™ at the Wake Forest Institute for Regenerative Medicine, using its bioprinting infrastructure through the nonprofit RegenMed Development Organization. The work will evaluate durability, integration with host tissue and resorption.⁷ It is animal and lab research, not a clinical trial.

9. The Material Has a Large-Volume Animal Study

Conexeu’s 12-month P.R.O.O.F. study reported meeting its objectives in a 200cc-equivalent model.¹⁵[*12] It tested the injectable form, not the printed matrix; it was run in animals; and the detailed findings are being prepared for peer review.

10. Wound Care Is the First Test

Before the breast program reaches the FDA, the same CXU™ material has to clear a nearer test. Conexeu says scaled-up batches met its predefined specifications and that its wound-care 510(k) submission remains on track for the first quarter of 2027.⁸ A clearance would be the platform’s first regulatory milestone; a delay would likely push back the programs built on it.

What’s Still Unproven, and Why It Still Matters

No preclinical device company comes without risk, and Conexeu is no exception. So far B.R.E.A.S.T.™ has not been tested in breast tissue or in people. None of the company’s cited studies evaluated CXU™ in breast tissue,⁶ and the Wake Forest program is animal and lab research, not a clinical trial; the device has not been submitted to or cleared by the FDA.⁷ Nobody knows yet how much volume a resorbing scaffold can hold in a breast, or for how long. The regulatory road is long: breast implants are among the most tightly regulated devices, in our view investors should expect human clinical trials, and the company has not given a timeline. Any new breast material will also have to show it doesn’t complicate cancer screening, the issue that ended Macrolane’s breast indication.¹⁴ Printing patient-specific tissue reliably, sterilely and affordably at scale is unproven. And others are moving: BellaSeno has reported interim clinical results with resorbable 3D-printed breast implants²⁶ and Tiger Aesthetics has invested in GenesisTissue’s printed implant in development.²⁷

The one thing to watch is the first data from the Wake Forest program on durability, integration and resorption.⁷

The Bottom Line

Breast reconstruction has spent 50 years getting better at replacing what was lost.²⁵ In our opinion, the next big shift in this market will come from whoever figures out how to help the body rebuild it instead.

Conexeu has pointed a platform it owns outright at a recurring market stuck on two options, where plans must cover reconstruction though not any particular product, and a preclinical program under way at the Wake Forest Institute for Regenerative Medicine before any human data exists.⁷ Behind it sits a wound-care program with a company-targeted FDA submission date using the same material.⁸

None of it is a clinical result.

Here’s what we’d watch over the next 12 months:

1. First results from the Wake Forest program on durability, integration and resorption.
2. The wound-care 510(k) submission in the first quarter of 2027, the company’s first planned FDA submission.
3. Clarity on the FDA pathway for B.R.E.A.S.T.™, and any reconstruction-focused partner.

Read the SEC filings and the underlying press releases, and talk to a qualified financial advisor before deciding anything.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →